Last update 22 Jun 2024
Dexketoprofen Trometamol
Last update 22 Jun 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Arveles, Desketo, Dexketoprofen + [23] |
Target |
Mechanism COX-1 inhibitors(Cyclooxygenase-1 inhibitors), COX-2 inhibitors(Cyclooxygenase-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Drug Highest PhaseApproved |
First Approval Date CN (27 Oct 2006), |
Regulation- |
Login to view First Approval Timeline
Structure
Molecular FormulaC16H14O3 |
InChIKeyDKYWVDODHFEZIM-NSHDSACASA-N |
CAS Registry22161-81-5 |
Related
74
Clinical Trials associated with Dexketoprofen Trometamol评价右酮洛芬氨丁三醇注射液治疗术后疼痛的有效性和安全性的随机、双盲、安慰剂平行对照、多中心的Ⅲ期临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial to evaluate the efficacy and safety of dexketoprofen tromethamine injection in the treatment of postoperative pain
评估右酮洛芬氨丁三醇注射液在中国健康受试者中的药代动力学研究—— 一项单中心、随机、开放的I期临床研究
[Translation] Evaluation of the pharmacokinetics of dexketoprofen tromethamine injection in healthy Chinese subjects: a single-center, randomized, open-label phase I clinical study
Comparison of Analgesic Efficacy of Dexketoprofen and Ibuprofen in Long Bone Fractures: Randomised Controlled Double-blind Study
100 Clinical Results associated with Dexketoprofen Trometamol
Login to view more data
100 Translational Medicine associated with Dexketoprofen Trometamol
Login to view more data
100 Patents (Medical) associated with Dexketoprofen Trometamol
Login to view more data
455
Literatures (Medical) associated with Dexketoprofen Trometamol22 Jan 2024Current drug metabolism
Effect of Dexketoprofen on the Disposition Kinetics of Moxifloxacin in Plasma and Lung in Male and Female Rats
Article
Author: Oguz, Halis ; Erdogan, Teslime ; Corum, Orhan
Background:::
The simultaneous use of NSAIDs and antibiotics is recommended for bacterial dis-eases in human and veterinary medicine. Moxifloxacin (MFX) and dexketoprofen (DEX) can be used simul-taneously in bacterial infections. However, there are no studies on how the simultaneous use of DEX affects the pharmacokinetics of MFX in rats.
Objectives:::
The aim of this study was to determine the effect of DEX on plasma and lung pharmacokinetics of MFX in male and female rats.
Methods:::
A total of 132 rats were randomly divided into 2 groups: MFX (n=66, 33 males/33 females) and MFX+DEX (n=66, 33 females/33 males). MFX at a dose of 20 mg/kg and DEX at a dose of 25 mg/kg were administered intraperitoneally. Plasma and lung concentrations of MFX were determined using the high-performance liquid chromatography-UV and pharmacokinetic parameters were evaluated by non-compartmental analysis.
method::
A total of 132 rats were randomly divided into 2 groups as MFX (n=66, 33 males/33 females) and MFX+DEX (n=66, 33 females/33 males). MFX at a dose of 20 mg/kg and DEX at a dose of 25 mg/kg were administered intraperitoneally. Plasma and lung concentrations of MFX were determined using the high-performance liquid chromatography-UV and pharmacokinetic parameters were evaluated by non-compartmental analysis.
Results:::
Simultaneous administration of DEX increased the plasma and lung area under the curve from 0 to 8 h (AUC0-8) and peak concentration (Cmax) of MFX in rats, while it significantly decreased the total body clearance (CL/F). When female and male rats were compared, significant differences were detected in AUC0-8, Cmax, CL/F and volume of distribution. The AUC0-8lung/AUC0-8plasma ratios of MFX were calculated as 1.68 and 1.65 in female rats and 5.15 and 4.90 in male rats after single and combined use, respectively
result::
Simultaneous administration of DEX increased the plasma and lung area under the curve from 0 to 8 h (AUC0-8) and peak concentration (Cmax) of MFX in rats, while it significantly decreased the total body clearance (CL/F). When female and male rats were compared, significant differences were detected in AUC0-8, Cmax, CL/F and volume of distribution. The AUC0-8lung/AUC0-8plasma ratios of MFX were calculated as 1.68 and 1.65 in female rats, and 5.15 and 4.90 in male rats after single and combined use, respectively.
Conclusion:::
MFX was highly transferred to the lung tissue and this passage was remarkably higher in male rats. However, DEX administration increased the plasma concentration of MFX in both male and female rats but did not change its passage to the lung. However, there is a need for a more detailed investigation of the difference in the pharmacokinetics of MFX in male and female rats.
other::
.
16 Dec 2023Translational neuroscience
Preoperatively administered single dose of dexketoprofen decreases pain intensity on the first 5 days after craniotomy: A single-centre placebo-controlled, randomized trial
Article
Author: Molnár, Csilla ; Fülesdi, Béla ; Szabó-Maák, Zoltán ; Andráskó, Dániel ; Csipkés, Csaba ; Kovács, Veronika ; Simon, Éva ; Buchholcz, Gyula ; Tankó, Béla
Abstract:
Background and purpose:
Headache attributed to craniotomy is an underestimated and under-treated condition. Previous studies confirmed the efficacy of preemptive analgesia with non-steroidal anti-inflammatory agents. The aim of the present work was to test the hypothesis of whether a single preoperatively administered dose of dexketoprofen (DEX) has the potency to decrease postcraniotomy headache (PCH) as compared to placebo (PL).
Patients and methods:
This is a single-centre, randomized, PL-controlled trial comparing the effect of a single oral dose of 25 mg DEX to PL on the intensity of PCH. Patients undergoing craniotomy were randomly allocated to DEX and PL groups. Patients rated their actual and worst daily pain using visual analogue scale (VAS) scores during intrahospital treatment (0–5 days) and 30 and 90 days postoperatively.
Results:
Two hundred patients were included. DEX decreased the worst daily pain intensity in the first 24 h only; the 5-days cumulative score of actual pain was 9.7 ± 7.9 cm for the DEX group and 12.6 ± 10.5 cm for the PL group, respectively (p = 0.03). This difference disappeared in the late, 30-, and 90-day follow-up period. No differences in VAS scores could be detected in supra- and infratentorial cases among the DEX and PL groups.
Conclusions:
A single preoperative dose of 25 mg of DEX slightly decreases the intensity of PCH in the first 5 days after craniotomy but it does not have an effect on chronic headaches and postoperative analgesic requirements.
01 Dec 2023Polish journal of microbiology
Do NSAIDs and Other Pain Relief Drugs Can Inhibit the Growth of Lactobacillaceae?
Article
Author: Tyski, Stefan ; Zawistowska-Rojek, Anna ; Kruszewska, Hanna
Abstract:
Non-steroidal anti-inflammatory drugs (NSAIDs) commonly used in clinical practice may cause gastrointestinal injuries and influence the gut microbiota. This study investigated the effects of various NSAIDs and some analgesics on the viability of Lactobacillaceae strains (including probiotic strains) in vitro. It was found that diclofenac, ibuprofen, ketoprofen, dexketoprofen, flurbiprofen, and acetylsalicylic acid inhibited the growth of lactobacilli at a concentration of 0.05−3.2 mg/ml. These MICs of NSAIDs are well above therapeutic plasma concentrations achieved in humans, indicating that the tested drugs should not inhibit the growth of lactobacilli in the human digestive tract.
100 Deals associated with Dexketoprofen Trometamol
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Dexketoprofen Trometamol |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Pain, Postoperative | CN | 29 May 2023 | |
| Migraine Disorders | CN | 27 Oct 2006 | |
| Pain | CN | 27 Oct 2006 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Pain | Phase 3 | CN | 04 Sep 2023 | |
| Low Back Pain | Phase 3 | CN | 04 Sep 2023 | |
| Analgesia | Phase 3 | CN | 16 Oct 2015 | |
| Back Pain | Phase 3 | CN | 15 Jul 2015 | |
| Renal Colic | Phase 3 | CN | 15 Jul 2015 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 641 | igzlwrgwrs(glmmjexxhi): P-Value = 0.019 | Positive | 01 Feb 2016 | |||
Phase 4 | 224 | (Dexketoprofen) | razfujgwjo(ammthbmaox) = vxizkvefah lsoumorzxb (ifismwkkcm, ucrzjobuif - lmjtfpjuft) View more | - | 23 Jul 2015 | ||
(Normal Slaline) | razfujgwjo(ammthbmaox) = hmotiqerab lsoumorzxb (ifismwkkcm, yfydzlvtfd - ldwfszzszb) View more | ||||||
Phase 1 | 26 | (Enantyum® Oral Solution) | nfwrtmkohi(hpfasbbywd) = lzqbyzgssb ofpvhbbbvp (dzuwazavex, cwoanttiqv - jlwygtwohb) View more | - | 09 Jul 2015 | ||
(Keral® Tablet) | nfwrtmkohi(hpfasbbywd) = kvxdftfqrd ofpvhbbbvp (dzuwazavex, tozbiwwawe - qxgbxoxxpy) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free